GlassScriptPhysician profile
Omar N Enriquez
NPI 1194822858
$6,157.36
in general payments reported to CMS, 2019-2025
27 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $32.95 · 2021: $240 · 2022: $879 · 2023: $1,558 · 2024: $918 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,926.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $917.74 | 2019-2025 | Giapreza, Xacduro, Zevtera |
| Abbvie INC. | $761.97 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $577.96 | 2019-2025 | |
| United Therapeutics Corporation | $457.17 | 2023-2025 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $432.91 | 2019-2023 | Andexxa |
| Kerecis Limited | $299.91 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Actelion Pharmaceuticals US, INC. | $298.38 | 2019-2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $293.21 | 2019-2023 | Xarelto |
| Mallinckrodt Hospital Products INC. | $249.26 | 2025 | Acthar, Terlivaz |
| Abbott Laboratories | $230.93 | 2022-2023 | Amplatzer Amulet |
| Merck Sharp & Dohme LLC | $189.12 | 2019-2025 | Zerbaxa |
| Chiesi USA, INC. | $166.63 | 2019 | |
| Ekos Corporation | $162.57 | 2019 | |
| Stryker Corporation | $152.54 | 2023 | Physio - Lucas |
| Medtronic, INC. | $133.24 | 2023 | Linq II |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Piramal Critical Care | $124.98 | 2022 | |
| Sobi, INC | $124.75 | 2024 | |
| Alcresta Therapeutics, INC. | $121.83 | 2024 | Relizorb |
| Insmed, INC. | $117.59 | 2023 | |
| Paratek Pharmaceuticals, INC. | $109.01 | 2025 | Nuzyra |
| Inari Medical, INC. | $100.22 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $49.98 | 2019 | |
| Gilead Sciences, INC. | $21.81 | 2023 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.20 | 2023 | |
| Genentech USA, INC. | $15.64 | 2019 | |
| Melinta Therapeutics, LLC | $14.68 | 2019 | |
| Mylan Specialty L.P. | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Enriquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.